Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:29:48 EDT Tue 28 Mar 2023
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:REGN - REGENERON PHARMACEUTICALS INC - http://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q826.97+6.560.8362.5298,3158,445824.00  827.36  819.22832.48  538.0118:10:0607:3015 min RT 2¢

Recent Trades - Last 10 of 8445
Time ETExPriceChangeVolume
18:10:06Q827.807.397
18:08:28Q825.505.091
17:41:23Q830.009.593
17:39:35Q827.406.9913
17:39:09Q827.306.8940
16:12:04Q826.976.562
16:10:57Q826.976.56217
16:07:57Q826.976.5629
16:02:17Q826.976.5696
16:02:15Q826.976.566

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2023-03-28 07:30U:REGNNews ReleaseSonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
2023-03-28 07:30U:REGNNews ReleaseRegeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
2023-03-23 02:00U:REGNNews ReleaseDupixent ‚ ® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
2023-03-22 07:00U:REGNNews ReleaseFDA Approves First-in-class Evkeeza ‚ ® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
2023-03-21 01:59U:REGNNews ReleaseDupixent ‚ ® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
2023-03-18 10:00U:REGNNews ReleaseDupixent ‚ ® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
2023-03-14 22:56U:REGNNews ReleaseStudents Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
2023-03-07 01:00U:REGNNews ReleaseDupixent ‚ ® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review